01:32 AM EDT, 07/27/2026 (MT Newswires) -- Idorsia (IDIA.SW) said Monday it is collaborating with Jamjoom Pharmaceuticals Factory (SASE:4015) for the commercialization and distribution of its insomnia drug Quviviq, or daridorexant, in Saudi Arabia and the Levant region in Asia. The Swiss biopharmaceutical group will supply the product, while Jamjoom Pharmaceuticals will secure the marketing authorization for the drug in the jurisdictions covered by the exclusive commercialization agreement. Idorsia will receive an upfront payment and additional payments under the deal.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.